Challenges in developing and studying treatments call for new ways of thinking about cancer research.

A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.

New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.

Findings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.

Adding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.